0001193125-24-005933.txt : 20240110 0001193125-24-005933.hdr.sgml : 20240110 20240110160800 ACCESSION NUMBER: 0001193125-24-005933 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 12 CONFORMED PERIOD OF REPORT: 20240104 ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Changes in Registrant's Certifying Accountant FILED AS OF DATE: 20240110 DATE AS OF CHANGE: 20240110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 24526662 BUSINESS ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-995-0900 MAIL ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 8-K 1 d78429d8k.htm 8-K 8-K
AILERON THERAPEUTICS INC NASDAQ false 0001420565 0001420565 2024-01-04 2024-01-04

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 4, 2024

 

 

Aileron Therapeutics, Inc.

(Exact Name of Registrant as Specified in Charter)

 

 

 

Delaware   001-38130   13-4196017

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

738 Main Street #398

Waltham, MA

   02451
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code: (617) 995-0900

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   ALRN   The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 3.01

Notice of Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

On January 4, 2024, Aileron Therapeutics, Inc., a Delaware corporation (the “Company”), received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) stating that the Company failed to hold its annual meeting of shareholders within twelve (12) months after its fiscal year ended December 31, 2022, as required by Nasdaq Listing Rule 5620(a) (the “Annual Meeting Listing Rule”). The Notice does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market.

The Notice states that the Company has 45 calendar days, or until February 20, 2024, to submit a plan to regain compliance with the Annual Meeting Listing Rule. The Company intends to file a definitive proxy statement for the Company’s 2023 Annual Meeting of Stockholders (the “2023 Annual Meeting”) with the Securities and Exchange Commission in January 2024. In addition, the Company intends to submit a plan (which will reflect calling and holding the 2023 Annual Meeting) to regain compliance with the Annual Meeting Listing Rule within the required timeframe. While the plan is pending, shares of the Company’s common stock will continue to trade on the Nasdaq Capital Market.

If Nasdaq accepts the Company’s plan, Nasdaq may grant the Company an extension of up to 180 calendar days from the Company’s fiscal year end, or until June 28, 2024, to regain compliance. The Notice further states that in determining whether to accept the Company’s plan, Nasdaq will consider such things as the likelihood that the annual meeting can be held within the 180-day period, the Company’s past compliance history, the reasons for the delayed meeting, other corporate events that may occur during the review period, the Company’s overall financial condition and its public disclosures. If Nasdaq does not accept the Company’s plan, the Company will have the opportunity to appeal the decision in front of a Nasdaq Hearing Panel.

 

Item 4.01

Changes in Registrant’s Certifying Accountant

On January 10, 2024, the Audit Committee of the Board of Directors of the Company appointed Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm for the fiscal year ended December 31, 2023. The Company formally engaged Marcum on January 9, 2024.

During the fiscal years ended December 31, 2023 and 2022, and the subsequent interim period from January 1, 2024 through January 10, 2024, neither the Company nor anyone on its behalf has consulted with Marcum with respect to either (i) the application of accounting principles to a specific transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company’s consolidated financial statements, and neither a written report nor oral advice was provided to the Company that Marcum concluded was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue; or (ii) any matter that was either the subject of a disagreement (as defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304 of Regulation S-K) or a reportable event (as defined in Item 304(a)(1)(v) of Regulation S-K).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    AILERON THERAPEUTICS, INC.
Date: January 10, 2024     By:  

/s/ Manuel C. Alves-Aivado

      Manuel C. Alves-Aivado, M.D., Ph.D.
      Chief Executive Officer
 EX-101.SCH 2 alrn-20240104.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 3 alrn-20240104_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Security Exchange Name Security Exchange Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 4 alrn-20240104_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 5 R1.htm IDEA: XBRL DOCUMENT v3.23.4
Document and Entity Information
Jan. 04, 2024
Cover [Abstract]  
Entity Registrant Name AILERON THERAPEUTICS INC
Security Exchange Name NASDAQ
Amendment Flag false
Entity Central Index Key 0001420565
Document Type 8-K
Document Period End Date Jan. 04, 2024
Entity Incorporation State Country Code DE
Entity File Number 001-38130
Entity Tax Identification Number 13-4196017
Entity Address, Address Line One 738 Main Street #398
Entity Address, City or Town Waltham
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02451
City Area Code (617)
Local Phone Number 995-0900
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol ALRN
Entity Emerging Growth Company false
XML 6 d78429d8k_htm.xml IDEA: XBRL DOCUMENT 0001420565 2024-01-04 2024-01-04 AILERON THERAPEUTICS INC NASDAQ false 0001420565 8-K 2024-01-04 DE 001-38130 13-4196017 738 Main Street #398 Waltham MA 02451 (617) 995-0900 false false false false Common Stock, $0.001 par value per share ALRN false EXCEL 7 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 8 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 10 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.4 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports alrn-20240104.xsd alrn-20240104_lab.xml alrn-20240104_pre.xml d78429d8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "d78429d8k.htm": { "nsprefix": "alrn", "nsuri": "http://www.aileronrx.com/20240104", "dts": { "schema": { "local": [ "alrn-20240104.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd" ] }, "labelLink": { "local": [ "alrn-20240104_lab.xml" ] }, "presentationLink": { "local": [ "alrn-20240104_pre.xml" ] }, "inline": { "local": [ "d78429d8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 4, "http://xbrl.sec.gov/dei/2023": 4 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 23, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation", "longName": "100000 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "duration_2024-01-04_to_2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78429d8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "duration_2024-01-04_to_2024-01-04", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "d78429d8k.htm", "first": true, "unique": true } } }, "tag": { "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "terseLabel": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "terseLabel": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "terseLabel": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "terseLabel": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Written Communications", "terseLabel": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "terseLabel": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "terseLabel": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "terseLabel": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "terseLabel": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "terseLabel": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security 12b Title", "terseLabel": "Security 12b Title", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.aileronrx.com//20240104/taxonomy/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 14 0001193125-24-005933-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-24-005933-xbrl.zip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